公开(公告)号：US20190321295A1

公开(公告)日：2019-10-24

申请号：US16425990

申请日：2019-05-30

Applicant: Novartis AG

Inventor： Keith A. Bowman ,  Noah Gardner ,  Travis Jeannotte ,  Chandra Vargeese

IPC: A61K9/127 ,  A61K48/00 ,  A61K31/7105 ,  C12N15/113 ,  C12N15/88 ,  A61K31/713

Abstract: Encapsulated nucleic acid nanoparticles of uniformly small particle size are produced by intersecting one or more nucleic acid streams with one or more lipid streams. The encapsulated nucleic acid nanoparticles include a nucleic acid encapsulated within a lipid nanoparticle host. Uniformly small particle sizes are obtained by intersecting an aqueous nucleic acid stream and a stream of lipids in organic solvent at high linear velocities and with total organic solvent concentrations less than 33%.

公开(公告)号：US10792361B2

公开(公告)日：2020-10-06

申请号：US16115883

申请日：2018-08-29

Applicant: Novartis AG

Inventor： Jeremy Lee Baryza ,  Rohan Eric John Beckwith ,  Keith Bowman ,  Crystal Byers ,  Tanzina Fazal ,  Gabriel Grant Gamber ,  Cameron Chuck-Munn Lee ,  Ritesh Bhanudasji Tichkule ,  Chandra Vargeese ,  Shuangxi Wang ,  Laura West ,  Thomas Zabawa ,  Junping Zhao

IPC: A61K47/18 ,  A61K9/127 ,  A61K9/51 ,  A61K31/713 ,  C07C217/58 ,  C07C219/06 ,  C07C229/12 ,  C07D317/28 ,  C07D295/096 ,  A61K9/00 ,  A61K38/22 ,  A61K47/22 ,  C07C229/14 ,  C07C235/42 ,  C07D205/04 ,  C07D213/69 ,  C07D213/79 ,  C12N15/113 ,  A61K48/00

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US10729775B2

公开(公告)日：2020-08-04

申请号：US16021193

申请日：2018-06-28

Applicant: Novartis AG

Inventor： Jeremy Lee Baryza ,  Rohan Eric John Beckwith ,  Keith Bowman ,  Crystal Byers ,  Tanzina Fazal ,  Gabriel Grant Gamber ,  Cameron Chuck-munn Lee ,  Ritesh Bhanudasji Tichkule ,  Chandra Vargeese ,  Shuangxi Wang ,  Laura Ellen West ,  Thomas Zabawa ,  Junping Zhao

IPC: A61K47/18 ,  C12N15/113 ,  A61K47/22 ,  C07D213/79 ,  C07D317/24 ,  C07D317/28 ,  C07D205/04 ,  C07D295/096 ,  C07D213/69 ,  A61K9/127 ,  C07C217/58 ,  C07C217/60 ,  C07C217/62 ,  C07C219/22 ,  C07C219/28 ,  C07C229/12 ,  C07C235/46 ,  C07C237/08

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US10124065B2

公开(公告)日：2018-11-13

申请号：US14779939

申请日：2014-03-06

Applicant: Novartis AG

Inventor： Jeremy Lee Baryza ,  Rohan Eric John Beckwith ,  Keith Bowman ,  Crystal Byers ,  Tanzina Fazal ,  Gabriel Grant Gamber ,  Cameron Chuck-Munn Lee ,  Ritesh Bhanudasji Tichkule ,  Chandra Vargeese ,  Shuangxi Wang ,  Laura West ,  Thomas Zabawa ,  Junping Zhao

IPC: C07C211/00 ,  A61K9/00 ,  C07C217/00 ,  A61K47/22 ,  A61K47/18 ,  C07C217/58 ,  C07C219/06 ,  C07C229/12 ,  C07D317/28 ,  C07D295/096 ,  A61K9/127 ,  A61K9/51 ,  A61K31/713 ,  A61K38/22 ,  C07C229/14 ,  C07C235/42 ,  C07D205/04 ,  C07D213/69 ,  C07D213/79 ,  C12N15/113 ,  A61K48/00

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US20180296677A1

公开(公告)日：2018-10-18

申请号：US16021193

申请日：2018-06-28

Applicant: Novartis AG

Inventor： Jeremy Lee Baryza ,  Rohan Eric John Beckwith ,  Keith Bowman ,  Crystal Byers ,  Tanzina Fazal ,  Gabriel Grant Gamber ,  Cameron Chuck-munn Lee ,  Ritesh Bhanudasji Tichkule ,  Chandra Vargeese ,  Shuangxi Wang ,  Laura Ellen West ,  Thomas Zabawa ,  Junping Zhao

IPC: A61K47/18 ,  C07C235/46 ,  A61K9/127 ,  C12N15/113 ,  C07D317/28 ,  C07D317/24 ,  C07D295/096 ,  C07D213/79 ,  C07D213/69 ,  C07D205/04 ,  C07C237/08 ,  C07C229/12 ,  C07C219/28 ,  C07C219/22 ,  C07C217/62 ,  C07C217/60 ,  C07C217/58 ,  A61K47/22

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US10342761B2

公开(公告)日：2019-07-09

申请号：US15326291

申请日：2015-07-10

Applicant: Novartis AG

Inventor： Keith A. Bowman ,  Noah Gardner ,  Travis Jeannotte ,  Chandra Vargeese

IPC: A61K9/127 ,  C12N15/88 ,  C12N15/113 ,  A61K31/7105 ,  A61K31/713 ,  A61K48/00

Abstract: Encapsulated nucleic acid nanoparticles of uniformly small particle size are produced by intersecting one or more nucleic acid streams with one or more lipid streams. The encapsulated nucleic acid nanoparticles include a nucleic acid encapsulated within a lipid nanoparticle host. Uniformly small particle sizes are obtained by intersecting an aqueous nucleic acid stream and a stream of lipids in organic solvent at high linear velocities and with total organic solvent concentrations less than 33%.

公开(公告)号：US20180369386A1

公开(公告)日：2018-12-27

申请号：US16115883

申请日：2018-08-29

Applicant: Novartis AG

Inventor： Jeremy Lee Baryza ,  Rohan Eric John Beckwith ,  Keith Bowman ,  Crystal Byers ,  Tanzina Fazal ,  Gabriel Grant Gamber ,  Cameron Chuck-Munn Lee ,  Ritesh Bhanudasji Tichkule ,  Chandra Vargeese ,  Shuangxi Wang ,  Laura West ,  Thomas Zabawa ,  Junping Zhao

IPC: A61K47/18 ,  C07C229/14 ,  A61K9/127 ,  A61K9/51 ,  C12N15/113 ,  C07D317/28 ,  C07D295/096 ,  C07D213/79 ,  C07D213/69 ,  C07D205/04 ,  C07C235/42 ,  A61K9/00 ,  C07C229/12 ,  C07C219/06 ,  C07C217/58 ,  A61K47/22 ,  A61K38/22 ,  A61K31/713 ,  A61K48/00

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.